Industry Analysis & Industry Trends
Patent cliff
The Cold Sore Medication Manufacturing industry has grown consistently over the past five years, even during the recession, when consumers preferred cheaper OTC medication over more expensive prescriptions. Most consumers come into contact with the herpes simplex virus by the age of 50, though the virus remains dormant most of the time. Because of the virus's prevalence, demand is highly stable for industry manufacturers. The patents of major companies' cold sore medications have expired or will soon expire, which opens the doors for cheap generic versions to flood the market. ... purchase to read more
Industry Report - Industry Investment Chapter
The Cold Sore Medication Manufacturing industry has a moderate level of capital intensity. For every dollar spent on labor, the industry spends about $0.22 on capital investment. Industry operators tend to have high overhead costs, while wages account for about 20.1% of total industry revenue. Capital investment typically includes spending on machinery and production facilities. The industry's products are often produced in mass quantities. However, some manufacturing functions, such as quality control, inspection and research and development (R&D) require higher levels of labor input. As companies continue to invest in R&D for new cold sore medication products, they will have to attract talented scientific personnel and offer competitive salaries. In... purchase to read more